BRUKINSA, the company's flagship BTK inhibitor, has become the market-leading product globally and in the U.S., with 2025 revenues of $3.9 billion (up 49% YoY). BeiGene delivered strong Q4 2025 results with product revenue of $1.5 billion in Q4 (up 32% YoY) and achieved GAAP profitability and significant free cash flow, marking an inflection point to scale and sustained earnings. For 2026, the company is guiding for revenue between $6.2 billion and $6.4 billion, with gross margins expected in the high 80% range and GAAP operating income of $700–800 million.
Cyborg Score Rationale
BRUKINSA holds market leadership in the BTK inhibitor category with strong long-term clinical outcomes. The company achieved profitability and significant free cash flow in 2025 while delivering 32% YoY product revenue growth. 2026 guidance projects continued strong growth to $6.2–6.4 billion in revenue with high gross margins and substantial operating income.
Top Insights
BRUKINSA is now the market-leading BTK inhibitor globally with superior long-term clinical outcomes versus competitors.
Company achieved GAAP profitability and significant free cash flow in 2025, signaling the beginning of sustained earnings growth.
Planned rebranding to BeOne Medicines and potential redomiciliation to Switzerland positions the company for expanded global sales channels, particularly in Europe and North America.
2026 guidance projects gross margins in the high 80% range, indicating strong pricing power and operational leverage.
Named Competitors
BRUKINSA — Market-leading BTK inhibitor for hematologic malignancies
Imbruvica — BTK inhibitor competitor
Calquence — BTK inhibitor competitor
Jazz Pharmaceuticals — Competing oncology company
Recent Developments
(Q4 2025) Delivered strong quarterly results with product revenue of $1.5 billion (up 32% YoY) and full-year BRUKINSA revenue of $3.9 billion (up 49%)
(2025) Achieved GAAP profitability and significant free cash flow, transitioning to sustained earnings
(2026 Guidance) Projected revenue of $6.2–6.4 billion with gross margins in the high 80% range and GAAP operating income of $700–800 million
(2025–2026) Announced rebranding initiative to BeOne Medicines with plans for potential redomiciliation to Switzerland
Open the full interactive BeiGene, Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.